Stargardt Research Updates 2024. If you have a question related to. Ocugen has made progress in its gene therapy programs for stargardt disease, retinitis pigmentosa, and geographic atrophy.
Stargardt disease causes progressive loss of central and night vision. The stargardt’s summit was held on february 29, 2024 with the goal to share the latest resources and information with the stargardt’s community.
22, 2024 (Globe Newswire) — Ocugen, Inc.
Ocgn), a leading biotechnology company focused on gene and cell therapies and vaccines, shared exciting updates.
The Foundation Fighting Blindness Completed A $6 Million Natural History Study For People Affected By Stargardt Disease.
Check out our extensive collection of clinical trial updates and our clinical.
Known As Progstar, The Study Has.
Images References :
(“Ocugen” Or The “Company”) (Nasdaq:
Six retinal layers were segmented and analyzed for changes in thickness.
The Foundation Fighting Blindness Completed A $6 Million Natural History Study For People Affected By Stargardt Disease.
Ocgn), a leading biotechnology company focused on gene and cell therapies and vaccines, shared exciting updates.
Check Out Our Extensive Collection Of Clinical Trial Updates And Our Clinical.